Title:
CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2019/163927
Kind Code:
A1
Abstract:
The present invention provides cross-species anti-latent TGF-beta 1 antibodies. The present inventors have conducted diligent studies and consequently created cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of TGF-beta 1 but do not inhibit integrin mediated activation of latent TGF-beta 1. It has been reported that latent TGF-beta is cleaved to release active TGF-beta by proteases. However, surprisingly, the present inventors have found that the anti-TGF-beta 1 antibodies inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting protease mediated cleavage of the LAP region of latent TGF-beta 1, and have in vivo anti-fibrotic effects as well. Further, antibodies of the invention are useful for the diagnosis or treatment of cancer, and can also be used in combination with immune check point inhibitors.
Inventors:
KANAMORI MASAKAZU (SG)
Application Number:
PCT/JP2019/006688
Publication Date:
August 29, 2019
Filing Date:
February 22, 2019
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
C07K16/30; A61K39/395; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12P21/08
Domestic Patent References:
| WO2017156500A1 | 2017-09-14 | |||
| WO2013134365A1 | 2013-09-12 | |||
| WO2011102483A1 | 2011-08-25 | |||
| WO2018043734A1 | 2018-03-08 |
Other References:
See also references of EP 3755723A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF:
Previous Patent: HIGH FLOW LOW PRESSURE CONTROL VALVE
Next Patent: FLUORINE RUBBER COMPOSITION AND CROSSLINKED FLUORINE RUBBER PRODUCT
Next Patent: FLUORINE RUBBER COMPOSITION AND CROSSLINKED FLUORINE RUBBER PRODUCT